1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
BUSINESS
President of Sawai Expects Generic Use Promotion in Next Medical Fee Revision
Mr Mitsuo Sawai, President of Sawai Pharmaceutical, said at a company results briefing on November 10 that more effective measures will be included to promote the use of generic drugs for the revision of medical and dispensing fees next year,…
To read the full story
BUSINESS
- Building New Plant in US Is Not a Solution to Potential Tariffs: Astellas CEO
February 25, 2025
- J&J to Terminate Business with Wholesaler Toho
February 25, 2025
- Antibiotic Fetroja Approved in South Korea: Shionogi
February 25, 2025
- Mitsubishi Tanabe’s Parkinson’s Drug Accepted for EMA Review
February 25, 2025
- Eisai Limits ALS Drug Shipment on Unexpectedly High Demand
February 21, 2025
In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…